Key Drivers
- High FY margins
- Meaningful leverage
- Intangibles risk
AIAI Summary
Genmab has shifted from a low‑risk royalty/partner profile into a higher‑beta, asset‑owning commercial biotech—creating meaningful upside from epcoritamab and the Merus assets but materially increasing solvency and valuation sensitivity due to heavy debt, concentrated intangibles and launch/integration execution risk. Monitor 2026 Phase‑III readouts, quarterly cashflow/deleveraging trends and Merus integration spend as binary catalysts that will quickly re‑rate the stock on either strong execution or downside impairments.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High FY margins
- •Meaningful leverage
- •Intangibles risk
GMAB posts strong annual profitability and cash generation with solid liquidity, but meaningful leverage, concentrated intangibles and pronounced quarterly volatility heighten solvency and impairment risk.
Price Behavior
Key Price Behavior Insights:
- •Strong downtrend
- •Elevated volatility
- •Resistance cluster
Stock down ~14% over the last month into the recent 2026-03-20 low, facing a $29.00–$30.00 short-term resistance band with elevated intraperiod volatility that raises downside risk and sets a clear breakout trigger.
Mid‑teens percent intraperiod range indicates unusually high short-term volatility
Sentiment & News
Key News Insights:
- •Equity compensation
- •Buyback completed
- •Leadership changes
Genmab executed coordinated equity-compensation and capital-structure moves—granting RSUs/warrants, completing a buyback and cancelling treasury shares—while maintaining investor outreach and disclosing significant institutional holdings.
These steps tighten share count, support EPS and signal governance stability, likely bolstering near-term investor confidence
Similar Companies in Healthcare
Other companies in the same sector with AI ratings